Cathay Biotech Inc

Maxio Technology expects net profit attributable to the parent company of approximately 517 million yuan in the first half of 2026, a year-on-year increase of around 821 percent, mainly driven by growing demand in the storage market and a steady rise in shipments of its PCIe series controller chips. Cathay Biotech and its subsidiaries have filed a lawsuit with the Beijing High People's Court against ten defendants, including Wang Zhizhou and Shandong Hanlin Biotechnology, for infringement of trade secrets, seeking economic damages of about 967 million yuan and reasonable expenses of 1 million yuan. The case has been accepted. XTC New Energy Materials released a preliminary earnings report, with first-half 2026 revenue of 14.488 billion yuan, up 91.09 percent year-on-year, and net profit attributable to the parent company of 491 million yuan, up 46.62 percent. In addition, Deep Principle completed a Series A3 funding round of nearly 1 billion yuan, Moji Technology completed a combined Series A and A+ funding round of 600 million yuan, and Magic Code Leap completed a seed funding round of tens of millions of yuan.